摘要:
The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof.
摘要:
The disclosure provides methods, and compositions for use in methods, for expanding lymphocyte populations in vitro, ex vivo, and in vivo using IL-15Rα/IL-15 activator complexes.
摘要:
A method for diagnosis or therapeutics of tumor which is characterized by administering an amount of a glycoprotein having a molecule capable of specifically binding to a lectin to a subject in need of such diagnosis or treatment and use of the glycoprotein for the manufacture of a diagnostic and therapeutic agent useful in detection or therapeutics of tumor are disclosed.